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Genetic factors have been postulated to be involved
in the etiology of diabetic peripheral neuropathy (DPN),
but their identity remains mostly unknown. The aim
of this study was to conduct a systematic search for
genetic variants influencing DPN risk using two well-
characterized cohorts. A genome-wide association study
(GWAS) testing 6.8 million single nucleotide poly-
morphisms was conducted among participants of
the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) clinical trial. Included were 4,384 white case
patients with type 2 diabetes (T2D) and prevalent
or incident DPN (defined as a Michigan Neuropathy
Screening Instrument clinical examination score >2.0)
and 784 white control subjects with T2D and no evidence
of DPN at baseline or during follow-up. Replication of
significant loci was sought among white subjects with
T2D (791 DPN-positive case subjects and 158 DPN-
negative control subjects) from the Bypass Angioplasty
Revascularization Investigation in Type 2 Diabetes (BARI
2D) trial. Association between significant variants and
gene expression in peripheral nerves was evaluated in
the Genotype-Tissue Expression (GTEx) database. A
cluster of 28 SNPs on chromosome 2q24 reached GWAS
significance (P < 5 3 1028) in ACCORD. The minor allele
of the lead SNP (rs13417783, minor allele frequency = 0.14)
decreased DPN odds by 36% (odds ratio [OR] 0.64, 95%CI
0.55–0.74, P = 1.93 1029). This effect was not influenced by
ACCORD treatment assignments (P for interaction = 0.6) or
mediated by an association with known DPN risk factors.
This locus was successfully validated in BARI 2D (OR 0.57,
95%CI 0.42–0.80,P=93 1024; summaryP=7.93 10212). In
GTEx, the minor, protective allele at this locus was asso-
ciated with higher tibial nerve expression of an adjacent
gene (SCN2A) coding for human voltage-gated sodium
channel NaV1.2 (P = 9 3 1024). To conclude, we have
identified and successfully validated a previously unknown
locus with a powerful protective effect on the development
of DPN in T2D. These results may provide novel insights
into DPN pathogenesis and point to a potential target
for novel interventions.
Diabetic peripheral neuropathy (DPN)—the most com-
mon cause of neuropathy worldwide—is a frequent com-
plication of diabetes that significantly contributes to the
increased morbidity and mortality associated with this
disease (1). Up to one-fourth of the annual U.S. expen-
diture on diabetes is due to DPN, a large proportion of
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which is secondary to type 2 diabetes (T2D) (2,3). The
most common presentation of DPN is a distal symmetric
polyneuropathy resulting from small and large fiber
dysfunction leading to loss of sensory, proprioception,
temperature, and pain discrimination, along with symp-
toms of numbness, tingling, burning, and shooting pain
(1,4). Signs and symptoms begin distally and spread
proximally.
Known risk factors for DPN include duration and
severity of hyperglycemia, age, dyslipidemia, hyperten-
sion, obesity, height, and smoking (1,5–9). Because
these exposures fail to fully explain interindividual
differences in the risk of developing DPN, genetic
factors have been postulated to be involved in the
etiology of DPN (10), although formal heritability
estimates, such as those available for other diabetic
complications, including cardiovascular autonomic neu-
ropathy (narrow-sense heritability up to 39%) (11–13),
are not available for DPN. Knowledge of the genetic
factors that modulate DPN risk may provide insights
into the molecular pathways linking the diabetic milieu to
nerve damage, which may in turn suggest new pharmaco-
logical targets for preventing or treating DPN. However,
although many genetic studies have been performed for
other diabetic complications (14), data on the genetic
determinants of DPN are scant. A few candidate gene
studies have been performed, but these were small and
not followed by replication attempts (10). A locus on
chromosome 8p21.3 was recently found to be associ-
ated with painful DPN in a genome-wide association
study (GWAS), but this finding did not reach genome-
wide significance and is still to be replicated (15).
Here we report the results of a GWAS for DPN con-
ducted among participants with T2D in the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) clin-
ical trial. Our findings, which were replicated in the
population of the Bypass Angioplasty Revascularization In-
vestigation 2 Diabetes (BARI 2D) trial, point to a locus on
chromosome 2q24 as a powerful determinant of DPN risk
that may act by affecting a nearby voltage-gated sodium
channel, NaV1.2, expressed in peripheral nerves. This is
the first GWAS of DPN yielding a genome-wide significant
signal with independent replication and biological plausi-
bility of the leading candidate gene in the associated
region.
RESEARCH DESIGN AND METHODS
Study Population
Discovery Set: ACCORD Study
The ACCORD clinical trial investigated whether cardiovas-
cular event rates could be reduced by intensively targeting
hyperglycemia to HbA1c ,6.0% (42 mmol/mol) compared
with a standard target of HbA1c between 7 and 7.9% (53–
63 mmol/mol). For this purpose, 10,251 participants with
T2D and high cardiovascular risk were randomized in a 1:1
ratio to receive intensive or standard glycemic control
therapy at 77 clinical sites across the U.S. and Canada
(16). The study also investigated the effect of intensive
versus standard blood pressure control and fibrate ver-
sus placebo therapy on cardiovascular events through the
ACCORD blood pressure and lipid subtrials in a double two-
by-two factorial design (16). In addition, ACCORD had a
rich follow-up of study participants and collected data on
other diabetic complications, including DPN, at baseline
and during follow-up. Of the 10,251 ACCORD participants,
8,174 consented to genetic studies. To minimize confound-
ing by race, our GWAS for discovery of genetic predictors
of DPN was restricted to 5,360 whites. Among them, DPN
data were collected from 5,168 participants at baseline
and/or during follow-up by means the Michigan Neuropathy
Screening Instrument (MNSI) clinical examination score.
Validation Set: BARI 2D Study
BARI 2D was a two-by-two factorial clinical trial enroll-
ing 2,368 participants with T2D and established coro-
nary artery disease (17). For glycemic control, participants
were randomly assigned to insulin sensitization or in-
sulin provision strategy to reach the same HbA1c target
of ,7.0% (53 mmol/mol). For coronary artery disease,
participants were randomly assigned to undergo coronary
revascularization procedures (percutaneous coronary in-
tervention or coronary artery bypass graft surgery) or
medical therapy. The aim was to investigate the cardio-
vascular event reduction by both treatment strate-
gies. As in ACCORD, other secondary outcomes were
obtained in BARI 2D, including DPN, which was evalu-
ated with the same MNSI clinical examination score at
baseline and follow-up (18). A total of 1,030 whites
consented to genetic studies in BARI 2D; 949 had genetic
data that passed internal quality control (QC) and also
had information about the presence of DPN at baseline
and follow-up. Because participants were recruited in
the two studies during the same time period (January–
June 2001 and February 2003–October 2005 for
ACCORD, and January 2001–March 2005 for BARI 2D)
and both studies upheld participation in another clinical trial
as an exclusion criterion (16,19), the chances of a person
being included in both studies were deemed to be negligible.
Outcome Definition
The ACCORD and BARI 2D trials both defined neuropathy
as an MNSI clinical examination score .2.0 (18,20)—
a criterion that has been extensively validated as being
highly sensitive and specific for the diagnosis of DPN
(21,22). The MNSI clinical examination includes a focused
examination of the feet to assess skin and structural
abnormalities, along with assessment of distal vibration
perception with a 128-Hz tuning fork and ankle reflexes.
For the purpose of the genetic association study, DPN case
subjects were defined as participants having anMNSI.2.0
at study entry and/or at any time during follow-up (4.9
and 5.3 years on average in ACCORD and BARI 2D,
respectively), whereas DPN control subjects were defined
presented as mean6 SD and were analyzed by independent
t test for difference in means between groups. Nonnormally
distributed continuous variables are presented as median
(interquartile range) values and were analyzed by t test
after log transformation. Categorical variables are pre-
sented as counts (percentages) and were analyzed by x2
tests to examine differences among groups.
GWAS
A GWAS for DPN was performed in 5,168 white ACCORD
participants. GWAS analyses were conducted separately in
ACCSET (3,554 case subjects/830 control subjects) and
ANYSET (600 case subjects/184 control subjects) using
SAS 9.4 software on the Harvard Medical School computing
cluster, Orchestra. After filtration for minor allele frequency
(MAF)$5%, 6,847,206 genotyped or imputed SNPs formed
the GWAS panel in each data set. For each common variant,
minor allele dosage (ranging from 0 to 2) was inferred from
the genotypes or computed from the imputed posterior
probabilities. The association between minor allele dosage
of each variant and DPN was tested by logistic regression,
assuming an additive genetic model and adjusting for
assignment to interventions, seven clinical center networks,
and top three principal components (PC1–PC3). After using
genomic control corrections (l = 1.014 for ANYSET and l =
1.032 for ACCSET), the GWAS results from the ACCSET and
ANYSET sets were meta-analyzed in METAL (Abecasis
Laboratory, University of Michigan, Ann Arbor, MI) (26),
through a fixed-effects inverse-variance approach. Genome-
wide significance was defined as a P value ,5 3 1028, and
suggestive (notable) significance as P , 1 3 1026. Man-
hattan and quantile-quantile (QQ) plots were generated to
illustrate the GWAS results.
Further analyses of SNPs reaching genome-wide sig-
nificance were carried out by 1) testing whether the SNP
had similar effects on prevalent DPN (MNSI .2.0 at
study entry) and incident DPN (MNSI #2.0 at baseline
and MNSI .2.0 during follow-up); 2) testing for inter-
action with baseline characteristics or, for incident DPN,
with trial treatments (intensive vs. standard glycemic
control, intensive vs. standard blood pressure control,
fenofibrate + statin vs. placebo + statin for hyperlipid-
emia control) by adding appropriate interaction terms; 3)
evaluating the association between SNP and baseline
characteristics, individual MNSI components, and other
diabetic complications, including cardiovascular auto-
nomic neuropathy and incident DNP and diabetic reti-
nopathy; 4) evaluating the association between DPN and
SNPs in African American participants; and 5) evaluat-
ing the association between DPN and genotyped low-
frequency variants (MAF 0.01–0.05) placed in the linkage
disequilibrium (LD) block as the top common SNP in the
GWAS.
Continuous and dichotomous outcomes were tested by
linear and logistic regression models, respectively. In-
cident outcomes were tested by means of Cox regression
models.
as participants having an MNSI #2.0 at study entry and 
for the entire duration of follow-up.
DNA Extraction and Genotyping
Discovery Set: ACCORD Study
Detailed DNA extraction, genotyping, QC methods, and 
imputation in ACCORD can be found in the supplementary 
material of the article in which the GWAS was first reported 
(23). In brief, genotyping was performed in two centers 
using different platforms and chips: 6,085 DNA samples 
(ACCORD UVA Set) were genotyped at the University of 
Virginia (UVA) on Illumina HumanOmniExpressExome-8 
(v1.0) chips containing 951,117 SNPs; 8,174 samples 
(ACCORD UNC Set) were genotyped at the University of 
North Carolina (UNC), on Affymetrix Axiom Biobank1 
chips containing 628,679 probes. The ACCORD UVA set 
included subjects who had given consent to genetic studies 
by any investigator; the ACCORD UNC included the subjects 
in the ACCORD UVA set plus those who had given consent 
only to studies by ACCORD investigators. After extensive 
QC of the individual genotyping sets and harmonization of 
genotypes for those samples and SNPs that were in common 
between the two genotyping sets, data were organized in 
two nonoverlapping data sets: ANYSET (n = 5,971), in-
cluding subjects from the ACCORD UVA set, genotyped at 
either UVA or UNC at a total of 1,263,585 individual SNPs, 
and ACCSET (n = 2,113), including subjects from the 
ACCORD UNC set minus those in the ACCORD UVA set, 
genotyped only at UNC at a total of 572,192 SNPs. 
Imputation was conducted independently in the ANYSET 
and ACCSET data sets by means of IMPUTEv2.3.1 (24) using 
the full 1000 Genomes Phase 3 (October 2014) panel as the 
reference. After discarding imputed SNPs with an informa-
tion content ,0.3, the total (genotyped + imputed) SNPs 
were 25,017,489 in ANYSET and 25,012,865 in ACCSET.
Validation Set: BARI 2D Study
DNA was isolated and purified from whole blood using 
the Qiagen QIAamp DNA purification kit (Qiagen, Ger-
mantown, MD), as previously described (25). Genotyping 
was performed using the Infinium Multi-Ethnic Global 
Array (Illumina, San Diego, CA) according to the manu-
facturer’s instructions. After indels, SNPs with call 
rates ,0.99, and multiallelic sites were filtered out, 
the samples were prephased with SHAPEIT and imputed 
toward the Phase 3 Cosmopolitan Reference panel of 
1000 Human Genomes project using IMPUTE2 software. 
Imputed genotypes were then converted into dosages 
using FCGENE software. Imputation quality ranged 
from 85 to 100% for the 40 variants available for valida-




Analyses were run in SAS 9.4 software (SAS Institute, 
Cary, NC). Normally distributed continuous variables are
Validation
All GWAS-significant SNPs (28 SNPs at locus 2q24) and
lead variants at loci that reached a P value of ,13 1025
in the discovery set (ACCORD) were tested for association
with DPN in a validation set derived from the BARI 2D
study. Logistic regression was used for this purpose with
adjustments by the following covariates: country of origin,
top three principal components, assignments to cardio-
vascular treatment strata (early medical therapy vs. early
revascularization with percutaneous coronary interven-
tion or coronary artery bypass grafting), and assignments
to glycemic control strata (insulin sensitization vs. insulin
provision). Given that replication was attempted for 13
variants, the significance threshold was set to P , 0.004
based on a Bonferroni correction (0.05/13). Variants that
were successfully validated in BARI 2D were tested for
their effects on prevalent DPN (MNSI .2.0 at the study
entry) and incident DPN (MNSI turned .2.0 during the
follow-up), as described for the discovery set.
Meta-analysis of BARI 2D and ACCORD
Results in BARI 2D were meta-analyzed with those in
ACCORD by means of METAL (Abecasis Laboratory, Uni-
versity of Michigan) using a fixed-effects inverse-variance
approach.
Power of Genetic Analyses
The discovery set (ACCORD) provided 80% power (a =
5 3 1028) to detect genetic effects corresponding to
a relative risk of 1.20 and 1.24 for effect allele frequen-
cies of 0.50 and 0.15, respectively. The validation set
(BARI 2D) provided 80% power (a = 0.0038, adjusting
for the 13 loci for which replication was sought) to detect
genetic effects corresponding to a relative risk of 1.26
and 1.32 for effect allele frequencies of 0.50 and 0.15,
respectively.
Expression Quantitative Trait Loci Analysis
The top variant from the GWAS was tested for association
with tibial nerve–specific gene expression through in silico
analyses using the Genotype-Tissue Expression (GTEx) v7
database (27). GTEx is an online database containing tissue-
specific gene expression data obtained from 620 donors (34%
females, 85% whites, 68% .50 years of age) by means of
Illumina TrueSeq RNA sequencing and the Affymetrix Hu-
man Gene 1.1 ST Expression Array and linked to GWAS data
obtained from the same individuals by whole-genome se-
quencing, whole-exome sequencing, or Illumina SNP arrays
(www.gtexportal.org). Expression quantitative trait loci
(eQTL) analyses of genes within62 mega base pairs (Mbp)
from the lead SNP were conducted among 361 genotyped
individuals for which tibial nerve tissue expression profiles
were available. Normalized effect sizes and their 95% CIs
were obtained from linear regression models testing the
association of the minor allele of the lead SNP with gene
expression adjusted by the top three genotyping principal
components, sex, genotyping platform, and a set of other
covariates described in the GTEx documentation (27).
Gene Expression Analysis for SCN2A
SCN2A is expressed in the human peripheral nervous
system in dorsal root ganglia (28). To quantify the level
of gene expression for SCN2A in the tibial nerve, RNA
sequencing (RNA-seq) samples from several human tissues
were contrasted: tibial nerve, hippocampus, and skeletal
muscle samples from the GTEx database (27) and dorsal
root ganglia samples from the study by North et al. (29).
Because library preparation, mapping, and relative abun-
dance quantification in transcripts per million (TPM) were
performed differently for these two studies, the meta-
analysis was performed as follows: Coding gene relative abun-
dances for 18,876 quantified coding genes were extracted from
the North et al. (29) study, and for each sample with nonzero
SCN2A abundance, the percentile of SCN2A expression with
respect to all coding genes in that sample were calculated.
For the GTEx data sets, the uniformly processed RNA-
seq abundances for coding genes were extracted from
the GTEx companion website database (GTEx_Analysis_
2016-01-15_v7_RNASeQCv1.1.8_gene_tpm.gct.gz) and renor-
malized by constraining the TPMs of all the 19,260 coding
genes quantified in the study to sum to 1 million. For each
sample with nonzero SCN2A abundance, the percentile of
SCN2A expression with respect to all coding genes in that
sample was calculated.
RESULTS
Clinical Characteristics of DPN Case Subjects and
Control Subjects
The clinical characteristics of the discovery and validation
sets are reported in Table 1. To minimize ethnic confound-
ing, both sets included only self-reported whites. The
discovery set consisted of 5,168 ACCORD participants:
4,384 who showed signs of DPN at study entry and/or
during follow-up (DPN case subjects) and 784 who did not
show signs of DPN at any time during the study (DPN
control subjects). Compared with the latter, DPN case
subjects were significantly older and taller, had longer
duration of diabetes, higher HbA1c, BMI, and urinary
albumin-to-creatinine ratio (UACR), and lower HDL cho-
lesterol, were more frequently treated with insulin, and
had a higher prevalence of self-reported retinopathy. For
many of these variables, differences with control subjects
were more pronounced for prevalent than incident case
subjects (Supplementary Table 1). The validation set con-
sisted of 949 BARI 2D participants, including 791 DPN
case subjects and 158 DPN control subjects, defined as
above. Overall, the clinical characteristics of the validation
set were similar to those of the discovery set, except for
lower HbA1c and cholesterol levels (Table 1). Within the
validation set, DPN case subjects had lower total and LDL
and HDL cholesterol and were more frequently treated
with insulin compared with DPN control subjects.
GWAS of DPN
A total of 6,847,206 common variants (MAF .0.05),
genotyped or imputed, were tested for association with
DPN in the discovery set. Of these, 28 reached genome-
wide significance (P , 5 3 1028), as summarized in the
Manhattan and QQ plots shown in Fig. 1. These variants
lie in the same region of chromosome 2q24 and are in
strong LD with each other in whites (Fig. 2A). When the
analysis was conditioned on the lead SNP (rs13417783),
the effects of all the other genome-wide significant var-
iants disappeared (Supplementary Fig. 1), indicating that
all 28 variants captured the same genetic effect. The lead
SNP had a MAF of 0.15 and was associated with a 36%
decrease in the odds of DPN per minor allele copy (odds
ratio [OR] 0.64, 95% CI 0.55–0.74; P = 1.93 1029) (Table
Table 1—Characteristics of DPN case and control subjects
Baseline characteristic












(n = 158) P value
Female 1,538 (35.1) 289 (36.9) 0.34 204 (25.8) 51 (32.3) 0.09
Age (years) 63.2 6 6.5 61.6 6 6.4 ,0.0001 63.33 6 8.47 62.09 6 9.29 0.10
T2D duration (years) 10.9 6 7.5 9.1 6 6.9 ,0.0001 10.5 6 8.38 9.06 6 8.71 0.05
BMI (kg/m2) 33.2 6 5.2 31.9 6 4.8 ,0.0001 31.8 6 5.41 32.33 6 5.97 0.27
Waist circumference (cm) 110.0 6 12.9 105.3 6 12.0 ,0.0001 108.99 6 13.08 108.42 6 13.97 0.62
Height (cm) 171.7 6 9.5 170.0 6 9.4 ,0.0001 NA NA NA
HbA1c (%) 8.22 6 0.93 8.11 6 0.90 0.02 7.54 6 1.54 7.66 6 1.63 0.40
Fasting glucose (mmol/L) 9.93 6 2.82 9.75 6 2.76 0.09 NA NA NA
SBP (mmHg) 135.2 6 16.7 134.7 6 16.4 0.42 131.65 6 20.6 128.75 6 16.32 0.05
DBP (mmHg) 74.1 6 10.4 75.0 6 10.7 0.03 73.82 6 11.92 73.54 6 11.22 0.78
LDL (mmol/L) 2.67 6 0.84 2.68 6 0.83 0.52 2.43 6 0.83 2.59 6 0.85 0.03
HDL (mmol/L) 1.04 6 0.27 1.06 6 0.29 0.0047 0.95 6 0.23 0.98 6 0.23 0.13
Women 1.16 6 0.29 1.22 6 0.29 0.0009 1.06 6 0.24 1.02 6 0.22 0.19
Men 0.97 6 0.23 0.98 6 0.23 0.54 0.91 6 0.21 0.96 6 0.24 0.02
Total cholesterol (mmol/L) 4.74 6 1.05 4.76 6 1.04 0.33 4.35 6 1.05 4.56 6 1.16 0.03
Triglycerides (mmol/L)† 1.95 (1.37–2.81) 1.91 (1.29–2.76) 0.14 1.76 (1.24–2.58) 1.90 (1.28–2.7) 0.46
eGFR (mL/min/1.73 m2) 87.8 6 21.7 90.4 6 20.4 0.0016 NA NA NA
UACR (mg/mmol)† 1.4 (0.7–4.2) 1.1 (0.6–2.8) ,0.0001 NA NA NA
Previous CV event* 1,556 (35.5) 264 (33.7) 0.33 318 (40.2) 69 (43.7) 0.42
Report of retinopathy 439 (11.3) 40 (5.6) ,0.0001 NA NA NA
Current smoker 496 (11.3) 84 (10.7) 0.8 63 (8) 19 (12.1) 0.09
Previous smoker 2,194 (57.0) 390 (56.2) 0.8 456 (57.8) 88 (56.1) 0.69
Insulin therapy 1,598 (36.5) 220 (28.1) ,0.0001 212 (26.8) 27 (17.1) 0.01
ACCORD Glycemia trial
Standard 2,227 (50.8) 371 (47.3) 0.07 — — —
Intensive 2,157 (49.2) 413 (52.7) — — —
ACCORD BP trial 1,862 (42.5) 361 (46.1) 0.06 — — —
Standard 926 (21.1) 182 (23.2) 0.81 — — —
Intensive 936 (21.4) 179 (22.8) — — —
ACCORD Lipid trial 2,522 (57.5) 423 (54.0) 0.06 — — —
Fibrate 1,294 (29.5) 219 (27.9) 0.86 — — —
Placebo 1,228 (28.0) 204 (26.0) — — —
BARI 2D CV intervention
Medical therapy — — — 398 (50.3) 67 (42.4) 0.07
Early revascularization — — — 393 (49.7) 91 (57.6)
BARI 2D diabetic therapy
Insulin provision — — — 394 (49.8) 71 (44.9) 0.26
Insulin sensitization — — — 397 (50.2) 87 (55.1)
Except where noted, data are means 6 SD for continuous variables and counts (%) for categorical data. BP, blood pressure; CV,
cardiovascular; DBP, diastolic blood pressure; NA, not available; SBP, systolic blood pressure. †Median (interquartile range). *Prior CV event:
In ACCORD, this includes secondary prevention status or history of myocardial infarction, stroke, angina, and/or ischemic changes
(electrocardiogram) on graded exercise tolerance test or positive imaging, coronary revascularization procedures, or other revascularization
procedures at baseline; inBARI 2D, this includes history ofmyocardial infarction, congestive heart failure, stroke, or transient ischemic attack.
2). While rs13417783 was an imputed variant (with
an excellent quality of imputation), other SNPs in the
genome-wide significant cluster were genotyped (Supple-
mentary Table 2). Effects were in the same direction in
both genotype sets of ACCORD (Supplementary Table 2).
Two other loci, rs13265430 on chromosome 8p23 and
rs77494074 on chromosome 11q25, attained P values in
the notable range (P = 13 1026 to 53 1028), and 10 more
attained P values in the 13 1025 to 131026 range (Table
2). All of these associations were only modestly affected by
adjustment for differences in age, diabetes duration,
and/or BMI (Supplementary Table 3). No evidence of
association was observed with the loci on chromosome
8 and 12, where a suggestive association with painful DPN
had been detected in a previous GWAS (15) (Supplemen-
tary Table 4). Of 14 polymorphisms that were previously
reported to be associated with DPN (30) and for which
data were available in the ACCORD GWAS, 1 (rs1963645
at theNOS1AP locus) showed a significant association with
DPN. However, this was in the opposite direction as that
previously reported (Supplementary Table 5).
Validation of GWAS Findings
The 13 independent loci that attained P, 13 1025 in the
GWAS were investigated for their association with DPN in
the validation set. The effect of the top GWAS locus (2q24)
was successfully replicated, with an OR of 0.57 per lead SNP
(rs13417783) minor allele copy (95% CI 0.41–0.80, P = 93
1024) (Table 2). One of the other 27 SNPs at 2q24 that were
GWAS-significant in the discovery set (rs10200297) showed
a stronger association than rs13417783 in the validation set
(Supplementary Table 6). However, in a meta-analysis of the
discovery and validation sets, rs13417783 remained the lead
SNP at this locus (OR 0.63, 95% CI 0.55–0.72, P = 7.9 3
10212). Among the other loci with P , 1 3 1025 in the
discovery set, one (rs10555080, aka rs72397229, on 19q12)
showed a nominally significant association with DPN in the
validation set (P = 0.0098), resulting in a P value in the
notable range (P = 2.6 3 1027) in the two sets combined.
Another locus (rs201655918 on 14q24) was also nominally
significant in the validation set, but the effect was in the
opposite direction than in the discovery set. Four loci
(rs1202660 on 7q11; rs2491019 on 10q22; rs11073752
on 15q25, and rs9948095 on 18p11) showed nonsignif-
icant associations in the validation set that were in the
same direction as in the discovery set. One of these SNPs
(rs11073752) attained a P value in the notable range (P =
6.5 3 1027) in the meta-analysis of the discovery and
validation sets.
Figure 1—GWAS results. A: Manhattan plot. Each dot represents a polymorphism (SNP). The x-axis depicts each chromosome and the
y-axis shows the negative log10 P value for association of each SNP with DPN. The red dotted line indicates the genome-wide signifi-
cance threshold of P = 53 1028; the gray dotted line indicates the notable genome-wide significance threshold of P = 13 1026. B: QQ plot
(inset). The black dashed line indicates the null hypothesis. The blue line represents the observed log10 P values corresponding to the ex-
pected P values. l = 0.994.
Figure 2—Characterization of locus 2q24. A: Regional association plot of locus 2q24. Variants are displayed 62 Mbp upstream and
downstream of the lead SNP (rs13417783). The x-axis depicts the chromosomal positions of the SNPs according to National Center for
Biotechnology Information Build 37, and the y-axis depicts the2log10 P values for association of these SNPs with DPN in ACCORD. SNPs in
strong LDwith the lead SNP (purple) aremarked in red (r2. 0.8). The bottom panel depicts genes from theUniversity of California, Santa Cruz
(UCSC) Known Genes data set within the region. The locus zoom plot was generated using LocusZoom (Abecasis Laboratory, University of
Michigan School of Public Health) through http://locuszoom.sph.umich.edu/genform.php?type=yourdata. The reference database was
hg19/1000 Genomes Nov 2014 European. B: eQTL analysis of locus 2q24 showing the association between rs13417783 and tibial nerve–
specific expression of neighboring genes. The eQTL analysis was conducted on data from the GTEx database (http://www.gtexportal.org/
home/). Genes were those located within 62 Mbp from the lead SNP rs13417783. *NES is the normalized effect size, i.e., the slope of the
linear regression between minor (T) allele dosage and gene expression. This effect size is computed in a normalized space where magnitude
has no direct biological interpretation. C: Tibial nerve–specific expression of AC019181.2 stratified by rs13417783 genotypes. D: Tibial


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2q24 Locus and DPN in African Americans
None of the 28 SNPs at the 2q24 locus showing GWAS-
significant association with DPN in whites were asso-
ciated with DPN in African Americans from ACCORD
(n = 1,345), as judged on the basis of a two-sided P ,
0.05. However, 15 of these SNPs had two-sided P ,
0.20, with effects going in the same direction as in
whites (OR 0.75–0.85) (Supplementary Table 6). The
strongest association was observed with rs16852735
(OR 0.75, two-sided P = 0.069, one-sided P = 0.034),
which in African Americans was not in LD (r2 = 0.02)
with the top SNP in whites (rs13417783). The number
of African Americans in BARI 2D was too small for
a meaningful analysis.
Low-Frequency Variants at 2q24 and DPN
On the basis of the findings with the common variants,
five low-frequency variants (MAF 0.01–0.05), which
were placed in the same LD block as the lead SNP
(rs13417783) and had been genotyped in ACCORD,
were tested for association with DPN among white par-
ticipants. All five variants, which were in high LD with each
other (r2 = 0.82–1.00), showed a significant association
with DPN (P, 0.01, based on a Bonferroni adjustment for
five comparisons) (Table 4). This association was some-
what attenuated but remained significant after adjustment
for rs13417783 (Table 4). Conversely, adjustment for any
of these low-frequency variants had minimal impact on the
magnitude of the association between the common variant
(rs13417783) and DPN (Table 4). Two of these variants
(rs1509652 and rs6755015) were genotyped in BARI 2D
and did not show any association with DPN (OR 0.94 and
OR 1.07, respectively, P . 0.05 for both), although power
for the analysis of low-frequency variants was limited in this
data set due to the smaller sample size.
Association Between 2q24 Locus and Gene Expression
The common variants associated with DPN at 2q24 span
80 kb of noncoding sequence placed between a cluster of
genes coding for NaVs (SCN1A, SCN2A, SCN3A, SCN7A,
and SCN9A) on the centromeric side and XIRP2 (xin
actin binding repeat containing 2) on the telomeric side
(Fig. 2A). In an eQTL analysis of GTEx data concerning
16 genes placed in a 2-Mbp radius from the lead SNP,
carriers of the rs13417783 minor allele had significantly
higher tibial nerve expression of SCN2A, coding for
NaVa subunit 2, and AC019181.2 (LOC101929633),
Table 3—Association between top loci and prevalent/incident DPN in ACCORD and BARI 2D
ACCORD BARI 2D
N case/N control
subjects OR (95% CI) HR (95% CI)
N case/N control
subjects OR (95% CI) HR (95% CI)
Case vs. control
subjects
Prevalent 2,547/784 0.64 (0.55–0.75) — 518/158 0.59 (0.42–0.83) —
Incident 1,837/784 0.65 (0.56–0.77) 0.80 (0.73–0.88) 271/158 0.59 (0.40–0.87) 0.69 (0.55–0.88)
Characteristics of the Association Between 2q24 Locus 
and DPN
The magnitude of the genetic effect at 2q24 in whites was 
similar if the analysis was restricted to prevalent or incident 
cases both in ACCORD and BARI 2D (Table  3). In ACCORD,  
no significant differences in the strength of the association 
were observed in relation to clinical characteristics, except for 
a significantly stronger effect among participants  with self-
reported diabetic retinopathy than in those  without this trait  
(P = 0.02) (Supplementary Fig. 2). No interaction was found 
with the intervention tested in ACCORD (i.e., intensive vs. 
standard glycemic control, intensive vs. standard blood pres-
sure control, and fenofibrate vs. placebo) (Supplementary Fig. 
3). When the MNSI score components were analyzed in-
dividually, the strongest association was seen with alterations 
of foot appearance (OR 0.71, P = 2  3 1027) and  ankle jerk  
(OR 0.76, P = 2 3 1025), followed by loss of vibration 
perception (OR 0.88, P = 0.04), whereas no association could 
be observed with foot ulcer (OR 1.00, P = 0.99). Nominally 
significant associations were observed between 2q24 
locus and triglycerides, estimated glomerular filtration 
rate (eGFR), and UACR at baseline (Supplementary Table 
7). As reported in the  Type 2 Diabetes Knowledge  Portal  
(http://www.type2diabetesgenetics.org), an association 
between triglycerides and the index SNP (rs13417783) 
as well as the other GWAS-significant SNPs in LD with it 
had been previously detected in the Genetics of Diabetes 
Audit and Research in Tayside Scotland (GoDARTS) 
study (P = 0.00011 for rs13417783). However, adjust-
ment for this variable or for the other two associated 
with 2q24 (eGFR and UACR) did not attenuate the 
association of this locus with DPN (Supplementary 
Table 8). Similarly, adjustment for age and duration 
of diabetes, which showed significant differences be-
tween case subjects and control subjects, had no effect 
(Supplementary Table 8). In addition, the association 
between the 2q24 locus and DPN was unaffected (OR 
0.64, 95% CI 0.54–0.77) by selecting control subjects 
who had a longer duration of diabetes (longer than the 
median of 7 years), and was only modestly reduced (OR 
0.73, 95% CI 0.60–0.89) by selecting older control 
subjects (older than the median age of 61 years). No 
association was detected between the 2q24 locus and 
risk of cardiac autonomic neuropathy or risk of micro-
and/or macrovascular complications (Supplementary 
Tables 9 and 10).
coding for an uncharacterized noncoding RNA (P = 9 3
1024 and P = 6 3 1024, respectively) (Fig. 2B–D). A
nominally significant association (P = 0.03) was also
detected with lower expression of the immediately ad-
jacent XIRP2 gene.
To gain further insight into SCN2A gene expression in
peripheral nerves, we contrasted SCN2A gene expression in
the hippocampus (a central nervous system tissue, serving
as a positive control), with dorsal root ganglion (DRG),
which contains the cell bodies of the neurons supplying the
axons to the sensory portion of the tibial nerve, tibial
nerves, and skeletal muscle, an excitable nonnervous system
tissue, serving as negative control. Coding gene relative
abundances (in TPMs) and their corresponding percentiles
are provided for all four tissues in Table 5, which includes
samples from both sexes. Abundant RNA signal for SCN2A
was found in both the hippocampus and in the DRG.
Although at lower levels, SCN2A was also consistently
expressed (in all but one sample) in the tibial nerve. By
contrast, it was undetectable in 80% of the samples of the
skeletal muscle samples and, in the remaining 20% of the
samples, was among the lowest in abundance across all
tissues.
DISCUSSION
Through a GWAS of the ACCORD cohort, we have iden-
tified a previously unrecognized locus on chromosome
2q24 having a powerful effect on the risk of DPN in
T2D. An association of similar strength was found between
this locus and DPN in BARI 2D. In both cohorts, the
2q24 minor allele conferred protection from DPN, being
more frequent in DPN-negative control subjects than in
DPN case subjects and the general population. In further
support of these findings, the same allele was found to be
associated with higher tibial nerve expression of a nearby
gene (SCN2A) coding for the a subunit of NaV1.2, pro-
viding a possible functional basis for the genetic effect
observed at the population level. This is the first report of
a DPN locus that reaches genome-wide significance in
a GWAS and is replicated in an independent study.
The fact that almost identical effects on DPN were
found for this locus in the discovery (OR 0.63) and
replication (OR 0.57) is remarkable and makes this finding
especially robust. Such a high degree of concordance
reflects the use of the same DPN definition (clinical
examination MNSI.2) in studies and the high sensitivity,
specificity, and correlation with abnormal nerve conduc-
tion characteristic of this DPN outcome (21,22). Other
contributing factors include the similar clinical character-
istics of the two cohorts with regard to height, BMI,
diabetes duration, blood pressure, and smoking status,
and the similar incidence of DPN, despite the administra-
tion of different interventions.
There are scant data in the literature to which our
findings can be compared because only one other GWAS of






























































































































































































































































































































































































































GoDARTS data sets, found suggestive evidence (P = 1.8 3
1027) for a DPN locus on chromosome 8p21 near GFRA2
(15). We could not replicate that finding in our study, and
conversely, no significant evidence for the locus 2q24 that
we identified in ACCORD and BARI 2D was reported in the
GoDARTS study. In addition to the possibility of the 8p21
locus being a false positive, given the lack of genome-wide
significance and previous replication, there are important
differences between the two GWASs that could explain
these discrepancies. First, the outcome considered by
the GoDARTS study was painful DPN, defined as a pre-
scription history of at least one of five drugs indicated
for the treatment of neuropathic pain along with a posi-
tive monofilament test for sensory neuropathy, which is
known to have low specificity. By contrast, in our GWAS,
DPN was defined by means of a validated instrument
(MNSI clinical examination) that does not include pain in
its assessment. Thus, the two studies captured different
aspects of DPN involving different components of the
peripheral nervous system (predominantly small fibers in
the case of painful DPN vs. large fibers in the case of
MNSI-diagnosed DPN).
Second, both ACCORD and BARI 2D were clinical trials,
with close follow-up, standardized outcome acquisition by
trained professionals, and strict adjudication, whereas the
GoDARTS study was based on medical record data col-
lected as part of routine medical care.
Finally, ACCORD and BARI 2D participants were char-
acterized by a long duration of diabetes (15 years on
average by the end of the study), which helped minimize
misclassification of control subjects—an essential feature
for the identification of protective effects on DPN, such as
that associated with the 2q24 locus. Although diabetes
duration was not specified in the GoDARTS report, it was
likely to be shorter owing to the population-based nature
of that cohort.
The DPN locus that we have identified may allow
clinicians to focus prevention efforts on patients at higher
risk of DPN. However, the real relevance of this finding lies
in the great potential for improving our understanding of
DPN biology and for identifying novel targets for pre-
ventive interventions. It is noteworthy in this regard that
the newly identified DPN locus is located in close vicinity to
a cluster of genes coding for the a subunits of NaVs, which
are responsible for multiple aspects of neuron excitability,
including thresholds for depolarizing responses and the
amplitude of action potentials (31). From the most proximal
to the most distal from the top variant, these genes
include SCN7A, SCN9A, SCN1A, SCN2A, and SCN3A, which
code for NaVx, NaV1.7, NaV1.1, NaV1.2, and NaV1.3,
respectively. In the GTEx database, the protective allele
of the 2q24 locus was significantly associated with higher
expression of one of these genes (SCN2A) in the tibial
nerve, supporting the hypothesis that increased activity of
the corresponding NaV1.2, which is expressed in DRG and
tibial nerve, may guard against the detrimental effects of
the diabetic milieu on peripheral nerves. SCN2A mRNA is
expressed by human and murine DRG neurons but not by
Schwann cells or other cell types that are found in the tibial
nerve (mousebrain.org), which suggests that the SCN2A
mRNA in the tibial nerve is contributed by sensory nerve
axons.
Rare mutations in the SCN2A gene have been implicated
in the etiology of neurodevelopmental diseases such as
autism spectrum disorder (loss of function mutations) and
infantile seizures (gain of function mutations) (32), but
the effect of these variants on susceptibility to DPN has
never been investigated due to the their rarity, nor has the
effect of NaV1.2 loss or gain of function been studied in
animal models of DPN. A relationship with DPN etiology
has been instead clearly established for NaV1.3 and
NaV1.7 (coded by SCN3A and SCN9A, respectively)
(33–36), but no differences in their expression were found
among 2q24 genotypes in the GTEx database. Whether
this was due to the small size and/or the lack of exposure to
diabetes of the samples in the GTEx database, or is related
to the fact that NaV1.3 and NaV 1.7 are preferentially
expressed in small fibers mediating pain transmission,
whereas theMNSI scoremainly tests large fibers mediating
vibration sense and tendon reflexes, remains to be
determined.
Altogether, these findings highlight the need for further
studies of the SCN genes in the 2q24 region as functional
mediators of the DPN locus and potential targets of novel
preventive interventions. These studies would include
testing of the association between the 2q24 genotype
and the expression of these genes in peripheral nerve
samples specifically collected from subjects with diabetes,
along with studies assessing the impact of overexpressing
or knocking down these genes in peripheral nerves
of animal models of DPN (37). The noncoding gene
AC019181.2 (LOC101929633), which also showed evi-
dence of association with the 2q24 locus in the GTEx
database, should be included in these studies given the
Table 5—Relative SCN2A abundance (in TPM) and corresponding percentiles across coding genes
Tissue
Fraction of samples with
detectable (TPM .0)
SCN2A expression
Mean SCN2A TPM (6 SD)
among coding genes in
samples with TPM .0
Mean SCN2A percentile (6 SD)
among coding genes in
samples with TPM .0
Hippocampus 123 of 123 18.8 6 15.8 71.7 6 14.9
DRG 21 of 21 18.1 6 6.0 49.0 6 6.6
Tibial nerve 413 of 414 2.0 6 1.8 30.8 6 5.7
Skeletal muscle 112 of 564 0.13 6 0.08 22.8 6 3.3
potential role of noncoding RNAs as regulators of gene
expression (38,39).
The genomic mechanisms linking this locus to differ-
ences in gene expression are unclear at this time. The index
SNP and the other 27 variants reaching GWAS significance
are in a noncoding region with quite subtle epigenetic
marks. The index SNP was found by ENCODE to be located
in a weak enhancer (as indicated by an H3K4m1 mark) in
human embryonic stem cells, but whether this regulatory
element is also active in neural cells remains to be de-
termined. Of the other 27 SNPs, the 2 highest ranking in
RegulomeDb are rs12993796 and rs16852735. The first
SNP is located in a DNA segment that binds BATF (a
transcription factor involved in the differentiation of
immune cells) in a lymphoblastoid cell line (GM12878).
The second SNP is placed in a region showing evidence of
binding to REST (RE1 silencing transcription factor) in
a neuroectodermic cell line (PFSK-1). REST is a transcrip-
tion factor that represses neuronal genes, including NaVs
(40). Because REST is expressed in peripheral nerves (as
shown by GTEx data) and in DRG, one can speculate that
the higher expression of SCN2A associated with the 2q24
protective allele in these tissues may be due to decreased
binding of this repressor to the DNA segment where
rs16852735 is located. The other 25 SNPs showed minimal
evidence of being functional in the summary provided by
RegulomeDb. Resequencing of the LD block in which the
GWAS-significant SNPs are located in large series of case
and control subjects, followed by ad hoc functional studies,
will be necessary to identify the causal variant(s) and
understand its (their) impact on genomic function.
Although the association with DPN was strongest at
2q24, another locus placed on chromosome 15q25 yielded
notable GWAS significance in the ACCORD GWAS as well
as in the meta-analysis with BARI 2D. Especially interest-
ing is the vicinity of this locus to the NTRK3 gene coding
for the receptor of neurotrophin 3, which, by prompting
the extension of fibers from proprioceptive DRGs to the
muscle spindle and the ventral horn of the spinal cord, is
responsible for inducing the synaptic connection between
sensory and motor neurons (41). On the basis of this evi-
dence, this locus should be considered as a prime candidate
for future studies, although the available GTEx data do not
suggest an association between the index SNP at 15q25 and
NTRK3 expression.
Strengths of our study include the advantages of clinical
trials, such as the rigorous and standardized protocols for
data acquisition, the regular follow-up, and access to rich
phenotype data, as well as the systematic GWAS approach
based on genotyped and imputed data of excellent quality
and wide coverage. As discussed above, the use of a vali-
dation cohort having very similar clinical characteristics to
the discovery cohort was another critical strength.
Nonetheless, some limitations should be acknowledged.
Because ACCORD and BARI 2D were both designed to
include participants with T2D at high risk of cardiovascular
disease, whether our findings could be generalized to
individuals with different characteristics or with type
1 diabetes remains to be determined. Similarly, our study
was limited to white subjects, and it is not known whether
these findings also apply to individuals of other races,
although the limited data on African American individuals
from ACCORD suggest that this might be the case. Also,
our study, while larger than most of the genetic studies of
DPN published thus far, was powered to detect only
relatively large genetic effects and the fact that control
subjects were slightly younger and had slightly shorter
diabetes duration than case subjects may have biased
results toward the null hypothesis. Therefore, other loci
having smaller yet functionally relevant effects may have
gone undetected. Finally, because the GWAS was limited to
common polymorphisms (MAFs .5%), the existence of
additional genetic effects due to less frequent variants
cannot be excluded.
In summary, we have identified and successfully vali-
dated a locus on chromosome 2q24 having a powerful
protective effect on the development of DPN in T2D.
Tissue expression analysis suggests that this effect may
be mediated by higher expression of the NaV1.2 in the
tibial nerve, which is known to increase neuronal excit-
ability. These results may provide novel insights into the
pathogenesis of DPN and point to a potential new target
for interventions aimed at preventing or treating this
complication of diabetes.
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